1·The international team of researchers found that blocking certain proteins stabilised the microtubules and made ovarian cancer cells more sensitive to paclitaxel.
国际研究小组的研究人员发现，阻断某些蛋白质可以稳定微管，使卵巢癌细胞对紫杉醇更敏感。
2·The median progression-free survival period with the drug combination was 11.8 months, twice as long as the 5.9 months achieved with paclitaxel alone.
药物联用的中值无进展存活期为11.8个月，是用单独紫杉醇获得的5.9个月的两倍。
3·Paclitaxel is a chemotherapy drug commonly used to treat breast and ovarian cancer, but some tumours can become resistant over time and start growing again.
紫杉醇是一种常用于治疗乳腺癌和卵巢癌的化疗药物，但是，随着用药时间的延长，一些肿瘤可以对其产生抗药性，而又开始生长了。
4·However, the knowledge out of this work can be applied for the heterologous production of other valuable terpenoid drugs like the mentioned artemisinin or paclitaxel.
然而，知识出这方面的工作可以用于异种生产其他有价值的萜类药物一样，提到青蒿素或紫杉醇。
5·Another 54 people did not receive paclitaxel in any form.
另外54人未接受任何形式的紫杉醇。